Cyclic peptide drugs approved in the last two decades (2001–2021)

Huiya Zhang and Shiyu Chen

Since insulin was first used in the clinic almost 100 years ago,1 the spectrum of potency, specificity and safety of the peptide chain enhanced by cyclization has demonstrated the fundamental characteristics of cyclic peptides. Among the > 60 FDA- and EMA-approved peptides,2 two-thirds are in the cyclic form and have an important role in the modern pharmaceutical industry.3 The constraint introduced by cyclization makes the peptide chain more conformationally stable, which improves the target protein binding affinity and reduces nonspecific binding due to fewer alternative conformations.4 Reduced conformational flexibility decreases the chance of the molecules fitting into the protease catalytic site and the proteomic resistance is improved.5 Cyclization also increases the efficacy of peptide chains by forming a larger interacting surface for intervening protein–protein interactions.6 Overall, peptide chain cyclization causes the cyclic peptides to be intrinsically different from linear peptides.7,8

Cyclization improves not only the structural properties of peptide chains but also the pharmacokinetic properties for absorption and biological membrane permeability that is necessary for reaching protein targets.9 The constrained structure of peptides can cause them to have a lower energy barrier for adapting to the membrane environment and binding to transporting proteins, which increases both passive diffusion and active transport.10 Cyclic peptides can also be further improved by introducing noncanonical elements to improve both their pharmacokinetic and pharmacodynamic properties.11 The introduction of lipophilic side chains greatly improves their affinity to plasma carrier proteins, helps them to avoid renal clearance and improves their pharmacokinetic properties.12,13 Alternative strategies, including conjugation with albumin and immunoglobulin to extend the half-life, are also commonly adopted, and the frequency of administration can be reduced.14,15

However, cyclization makes the development of cyclic peptide drugs more challenging compared to the development of linear peptides.4,16 The majority of approved cyclic peptides are engineered from natural analogs by keeping the overall cyclic peptide structure to maintain affinity to the target protein.17,18 Canonical peptide chains are conventionally cyclized by head–tail amidation, disulfide bond formation between cysteines, and sidechain amine to C-terminal carboxyl group and sidechain carboxyl group to N-terminal amidations.19–21 More recently, peptide cyclization was advanced by the introduction of noncanonical elements that can induce cyclization of orthogonal reactive groups.22,23 The introduction of noncanonical elements in cyclic peptides expanded not only the chemical space of cyclic peptides but also the library diversity, which is very important for screening potent ligands.21 The combination of these developments in diverse chemical and biological technologies contributed to the rapid development of cyclic peptide drug discovery.4

In this review, we summarize the discovery and development of cyclic peptides that have been approved in the last two decades. Chemical structures, mechanisms of action and metabolic properties are analyzed to unveil the important factors for cyclic peptide drug development and utilization in clinical...
situations. We mainly focus on cyclic peptide therapeutics by excluding peptides with >20 amino acids that show properties similar to small proteins and peptidomimetics with <5 residues that show physical properties similar to small molecules. Taking advantage of many recently developed technologies for building cyclic peptide libraries with a diversity of billions by translating genetic variations, cyclic peptides with a length in this range can be routinely screened and rapidly synthesized for hit discovery and affinity maturation to obtain cyclic peptides suitable for drug development. The opportunities and perspectives for cyclic peptide drug development are also discussed.

Targeting intracellular proteins

Developing cell permeable cyclic peptides that can reach intracellular targets is a challenging task. Unlike small molecules that enter cells primarily through passive diffusion, peptide-based molecules greater than 1000 Da have distinct physical properties, mechanisms, and cell permeability ability, and currently available theories for improving the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of small molecules do not apply to the development of cyclic peptides. Available theories for designing cell permeable peptides, such as passive diffusion, endocytosis and carrier-mediated transport with (CPPs), are limited in many aspects. It is well known that CPPs bind to several extracellular receptors and can be actively imported. It is necessary to incorporate specific elements in the sequence of the peptide chain, and these chemical alterations can impact the conformation of peptide drugs and further reduce the target binding affinity. Improving the hydrophilic and lipophilic characteristics of peptides with modification strategies such as N-methylation, side chain lipidation, and introduction of D-amino acid substituents can all increase the general ability of peptides to pass through lipid bilayer-based cell membranes. However, the fundamental difficulty associated with developing cell-permeable peptides is the lack of knowledge on the mechanisms associated with cell penetration. Five properties, including hydrogen-bonding potential, conformation, charge, size, and hydrophobicity, were observed to influence cell permeability. The extra stability of cyclization introduced into cyclic peptides makes them ideal candidates for entering cells through endocytosis, which requires a resistance to the variety of enzymes present in lysosomes.

Romidepsin (1, Table 1 and Fig. 1a) and voclosporin (2, Table 1 and Fig. 1a) are the only two cyclic peptides approved in the past two decades that target intracellular protein targets. Romidepsin is a natural bicyclic peptide obtained from the bacterium *Chromobacterium violaceum* in 1994 and approved by the FDA in 2009 for cutaneous T-cell lymphoma (CTCL). Romidepsin is a rather small depsipeptide that contains a head–tail lactone cyclization and a pair of disulfide bridges. Although romidepsin can be chemically synthesized, the primary source of romidepsin was manufactured by fermentation. Romidepsin is a prodrug in which the disulfide is reduced to two thiols in the intracellular matrix. Once

![Table 1](image)

<table>
<thead>
<tr>
<th>No.</th>
<th>Trade name</th>
<th>Generic name</th>
<th>Target</th>
<th>Indication</th>
<th>Route of admin.</th>
<th>Company</th>
<th>Sales 2020</th>
<th>Ring size (Aa)</th>
<th>Cyclization type</th>
<th>Hydrophilic</th>
<th>Basic</th>
<th>Acidic</th>
<th>N-Me</th>
<th>Polar</th>
<th>Charge</th>
<th>N-acyl</th>
<th>Lipidation</th>
<th>D-amino acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IstoDax</td>
<td>Romidepsin</td>
<td>Histone deacetylases</td>
<td>Anticancer</td>
<td>IV fusion</td>
<td>Celgene Inc.</td>
<td>N. A.</td>
<td>N. A.</td>
<td>3RQD</td>
<td>Lactone and disulfide</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>Lupkynis</td>
<td>Voclosporin</td>
<td>Calcineurin</td>
<td>Lupus nephritis</td>
<td>Oral</td>
<td>Aurinia Inc.</td>
<td>N. A.</td>
<td>N. A.</td>
<td>3ODI</td>
<td>Head–tail</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>

a Based on the physical properties of the sidechains of the canonical amino acids, Ala, Gly, Ile, Leu, Met, Phe, Val, Pro and Lys are categorized as hydrophobic; Asn, Gln, Ser, Thr, Trp and Tyr are categorized as basic; and Asp and Glu are categorized as acidic. The noncanonical amino acids are categorized similarly as the canonical analogs.
reduced, thiols can chelate zinc in the zinc-dependent active site of histone deacetylase (HDAC) enzymes, thereby inhibiting histone deacetylases and inducing cell apoptosis. The half-life of intravenously administered romidepsin is approximately 3.5 hours. In rats, the primary route of elimination of romidepsin and its metabolites is the bile with subsequent excretion in feces, and approximately 20% hepatic clearance is metabolized. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.

Fig. 1 The chemical structures of cyclic peptides from Tables 1 and 2 that target (a) intracellular proteins and (b) extracellular proteins.
Recently, Istodax was withdrawn as a treatment for peripheral T-cell lymphoma, while it remains on the market for treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy.43

Voclosporin was recently approved by the FDA for the treatment of lupus nephritis (LN) on January 22, 2021.44 Voclosporin was developed from ciclosporin with enhanced potency and metabolic stability.45 The rationale of the optimization is to replace the butenyl group of the first residue 4-[(E)-2-butenyl]-1,N-dimethyl-L-threonine (Bmt1) in ciclosporin A (CsA) with 4-[(2E,4E)2,4-pentadienyl]-1,N-dimethyl-L-threonine (E-MePmt1) to optimize its fit against the hydrophobic Cn surface to increase the binding affinity.46,47 Voclosporin is 11 residues long containing a single ε-amino acid with head–tail cyclization. Some of the amino acid substrates become N-methylated by S-adenosyl methionine.48 Voclosporin plays an important role in inhibiting T-cell proliferation and preventing the release of proinflammatory cytokines by blocking the activity of the calcium-regulated serine-threonine phosphatase calcineurin.49

**Targeting outer membrane proteins**

Half of the cyclic peptides approved in the last twenty years target extracellular protein targets, which primarily interact with G protein-coupled receptors (GPCRs). So far most GPCR-targeting therapeutics are small molecules;50 in contrast, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids),51 which suggests that this class of molecules could be therapeutically useful for being modified to develop peptide-based therapeutics. However, the short half-life of most naturally occurring linear and temporary peptide ligands severely hinders their development as drugs. The goal of developing peptide-based therapeutics from endogenous ligands is to preserve and exploit the native properties of high affinity, selectivity and potency while at the same time improving the unfavorable pharmacokinetic properties including the short half-life, rapid degradation, high levels of clearance, and even the oral bioavailability by overcoming gastrointestinal degradation and poor membrane permeability.52,53 Although peptide therapy with a short half-life is desirable in some cases, extending the half-life of peptide therapies is one of the primary goals of drug development.54 Cyclization, a common strategy applied to rigidify the conformation of the peptide chain, can benefit the development of peptide-based therapeutics by increasing the plasma half-life and reducing enzymatic metabolism and renal elimination. In the past two decades, nine cyclic peptides that target membrane proteins were approved for clinic use (Table 2 and Fig. 1b). The ring size and amino acid composition were also summarized for comparison with the cyclic peptide therapeutics targeting intracellular proteins, and a trend in the population of more hydrophobic amino acids in the cell-penetrating peptides can be observed.

Ziconotide (3, Table 2 and Fig. 1b) is a synthetic version of ω-conotoxin MVIIA (ω-MVIIA) isolated from the venom of the snail Conus magus. ω-MVIIA contains 25 residues, and 6 of the
amino acids are cysteines that are linked in three pairs of disulfide bonds. The NMR structure revealed that α-MVIIA has a stable antiparallel β-sheet structure in solution. As a potent and selective blocker of N-type calcium channels, ziconotide was approved for the treatment of severe chronic pain in 2004. Evidence suggests that ziconotide delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission. Ziconotide has only limited ability to cross the blood–brain barrier. To achieve optimal analgesic efficacy with reduced potential for serious side-effects, ziconotide must be administered intrathecally.

Linaclotide (4, Table 2 and Fig. 1b), an orally administered 14-amino acid synthetic peptide, is a first-in-class, high-affinity guanylate cyclase C agonist (GCCA) developed in the 1990s. Linaclotide is homologous to the paracrine peptide hormones guanylin and uroguanylin and was modified to confer a higher binding affinity as a guanylate cyclase C (GC-C) agonist along the longitudinal axis of the gastrointestinal tract regardless of changes in pH between 5 and 8. The active conformation of linaclotide is stabilized by three intramolecular disulfide bridges and developed for the treatment of irritable bowel syndrome with constipation (IBS-C). Linaclotide is homologous to the paracrine peptide hormones guanylin and uroguanylin and was modified to confer a higher binding affinity as a guanylate cyclase C (GC-C) agonist along the longitudinal axis of the gastrointestinal tract regardless of changes in pH between 5 and 8. The active conformation of linaclotide is stabilized by three intramolecular disulfide bridges and developed for the treatment of irritable bowel syndrome with constipation (IBS-C).

Plecanatide (5, Table 2 and Fig. 1b) is a 16-amino-acid peptide nearly structurally identical to human uroguanylin apart from the substitution of Asp3 with Glu3. Plecanatide is constrained by two pairs of disulfide bridges and adopts active conformations for binding guanylate cyclase-C (GC-C) receptors at pH 5.0, the pH value of the duodenum and proximal jejunum. Activation of GC-C receptors in the GI tract stimulates intracellular production of cyclic guanosine monophosphate (cGMP), which then activates cystic fibrosis transmembrane conductance regulators (CFTRs) and cGMP-dependent protein kinase G-II. The activation of both CFTRs and cGMP-dependent protein kinase G-II produces an efflux of chloride ions from enterocytes lining the GI tract, resulting in an efflux of water into the intestinal lumen. As with most orally ingested peptides, plecanatide is degraded by intestinal enzymes, and a very little amount of the active drug enters systemic circulation.

Pasireotide (6, Table 2 and Fig. 1b) is the second-generation analog of somatostatin, a naturally occurring inhibitory hormone that interacts with G protein-coupled somatostatin receptors and blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Pasireotide has a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide is a hexapeptide with head-to-tail cyclization. Pasireotide binds with a higher affinity to somatostatin receptor 1 (SSTR1, 30-fold), SSTR3 (5-fold), and SSTR5 (39-fold) and with the same affinity to SSTR2 when compared with octreotide, a higher affinity to SSTR1 (19-fold), SSTR3 (9-fold), and SSTR5 (106-fold), and the same affinity to SSTR2 (2-fold) when compared with lanreotide. Pasireotide was approved for the treatment of Cushing’s disease by the EMA and FDA in 2012. Pasireotide LAR was approved by the FDA for the treatment of acromegaly in December 2014.

Lanreotide (7, Table 2 and Fig. 1b) is also an octapeptide analog of somatostatin, and it was cyclized by a pair of disulfides formed between cysteine 2 and cysteine 7. Several strategies were developed for extending the half-life of lanreotide. Slow-release formulation, lanreotide sustained release (lanreotide SR), has an extended half-life of 4.5 days. Lanreotide embedded in the microspheres of biodegradable polymers can be administered at a dose of 30 or 60 mg every 7–14 days. Lanreotide was approved for acromegaly treatment in Europe in the 1990s. The FDA approved lanreotide for the treatment of acromegaly in 2007, metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETS) in 2014 and for the treatment of carcinoid syndrome in 2017.

Vasopressin (8, Table 2 and Fig. 1b) is an antidiuretic hormone developed from a natural nonapeptide with nine amino acids cyclized by a disulfide bond between Cys4 and Cys9. Vasopressin was discovered in 1928, and its sequence was elucidated in 1951. In humans, vasopressin is encoded by the mRNA for preprovasopressin II. Vasopressin is non-selective with affinity for activating vasopressin V1a, V2, and V1b, and oxytocin receptors. Vasopressin mediates vasoconstriction by activating the V1 receptor, consequently promoting antiuresis activity and exerting procoagulant activity on vascular smooth muscle. Vasopressin was branded as Pitressin and marketed for clinical use almost 100 years ago. Par Sterile Products received new drug applications (NDAs) from the FDA for branding Vasostrict in hypotensive adult patients with vasodilatory shock. Vasopressin shows great advantages over other medications in the treatment of septic shock by increasing blood pressure.

Terlipressin (9, Table 2 and Fig. 1b) is a synthetic long-acting vasopressin analog with a half-life of 6 hours in contrast to 10 min for vasopressin. Terlipressin acts on vasopressin receptors V1a, V1b and V2, and has an improved safety profile and fewer side effects than vasopressin. Terlipressin is metabolized by endopeptidases to form lysine vasopressin by removing the triglycine residues at the N-terminal end of the cyclic peptide. Terlipressin has similar effects, but this drug has been used in far fewer patients.

Bremelanotide (10, Table 2 and Fig. 1b) is a heptapeptide cyclized between the sidechains of Asp2 and Lys7 to form the lactam analog of α-melanocyte-stimulating hormone (α-MSH). Bremelanotide was originally developed as a potential sunscreen tanning agent and accidentally discovered to cause sexual arousal. Bremelanotide is a non-selective agonist of melanocortin receptors, primarily of the MC3 and MC4 receptors. Activation of G-protein coupled MC receptors will cause increased intracellular production of cAMP, calcium mobilization and receptor internalization, and subsequently activates dopamine terminals in the medial preoptic area (MPOA). Dopamine (DA) released in the
**Antimicrobial cyclic peptides**

The high potency and low toxicity of cyclic peptides make them ideal for developing antimicrobials for targeting microbial proteins that have no or low similarity to human proteins.\(^\text{104}\)

In the past two decades, four antibacterial and three antifungal cyclic peptides were approved for clinical use (Table 3 and Fig. 2). All of these cyclic peptides were developed from natural metabolic products that were evolved and produced by organisms for eliminating competitors.\(^\text{105}\) The application of cyclic peptides in developing antimicrobials demonstrates the strength of their stable structure in binding to relatively small targets, which can only be achieved by large proteins in traditional beliefs.\(^\text{105}\) The action of cyclic peptides depends on a combination of secondary structure, charge, and hydrophobicity and amphipathicity properties, distinct from small molecules’ binding mode.\(^\text{105}\) In this section, the structures and action mechanisms of selected antimicrobials will be described and discussed for unveiling the importance of cyclic peptides.

**Table 3** Antibiotics and antifungals derived from cyclic peptides approved in the last two decades

<table>
<thead>
<tr>
<th>No.</th>
<th>Trade name</th>
<th>Generic name</th>
<th>Target</th>
<th>Indication</th>
<th>Approval</th>
<th>PDB</th>
<th>Route of admin.</th>
<th>Cmax(^a) (nM)</th>
<th>HT (h)</th>
<th>Company</th>
<th>Sales 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Cubicin</td>
<td>Daptomycin</td>
<td>Membrane pore formation</td>
<td>Antibiotic</td>
<td>2005</td>
<td>1TSN IV</td>
<td>11,3400</td>
<td>7.7</td>
<td>Merck Sharp &amp; Dohme Corp.</td>
<td>$152 M</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Vibativ</td>
<td>Telavancin</td>
<td>Cell wall synthesis</td>
<td>Antibiotic</td>
<td>2009</td>
<td>IV fusion</td>
<td>57,400</td>
<td>8</td>
<td>Cumberland Inc.</td>
<td>N. A.</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Dalbavancin</td>
<td>Dalbavancin</td>
<td>Cell wall synthesis</td>
<td>Antibiotic</td>
<td>2014</td>
<td>3RUL IV fusion</td>
<td>15,800 346</td>
<td>Melinta Inc.</td>
<td>N. A.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Orbacvit</td>
<td>Orbacvit</td>
<td>Cell wall synthesis</td>
<td>Antibiotic</td>
<td>2014</td>
<td>IV fusion</td>
<td>77,000</td>
<td>245</td>
<td>Allergan Ltd.</td>
<td>N. A.</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Cancidas</td>
<td>Caspofungin</td>
<td>1,3-Beta-glucan synthase</td>
<td>Antifungal</td>
<td>2001</td>
<td>2N2Q IV</td>
<td>8450</td>
<td>27</td>
<td>MERCK &amp; CO., Inc.</td>
<td>$430 M</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Mycamine</td>
<td>Micafungin</td>
<td>1,3-Beta-glucan synthase</td>
<td>Antifungal</td>
<td>2005</td>
<td>IV</td>
<td>7815</td>
<td>13.4</td>
<td>Astellas Inc.</td>
<td>$349 M</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Eraxis</td>
<td>Anidulafungin</td>
<td>1,3-Beta-glucan synthase</td>
<td>Antifungal</td>
<td>2006</td>
<td>IV fusion</td>
<td>9500</td>
<td>50.3</td>
<td>Pfizer</td>
<td>N. A.</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Pharmacokinetic data was cited from FDA approval summaries.
differentiated.123 The constancy of the peptide is responsible for binding to the \( \alpha \)-alanyl-\( \beta \)-alanine motif, and the sidechain functional groups are derivatized to improve the properties of the peptide.124 Dalbavancin possesses a potent and rapid antibacterial activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including \textit{Staphylococcus aureus}, MRSA, \textit{enterococci}, and \textit{streptococci}.124,125 Precursor glycopeptides of dalbavancin is manufactured by fermentation of a selected \textit{Nonomuraea} strain, followed by carboxyl amidation and saponification for increased potency against staphylococci, particularly CoNS.126 The lipophilic side chain of dalbavancin has the common function of anchoring in the bacterial membrane, which is attributed to the increased affinity of dalbavancin for its target. The final dalbavancin is a compound mixture composed of five subtypes, with approximately 90% as B0,127 which has a longer half-life of approximately 1 week compared with that of vancomycin which is only 4 to 6 hours.128,129 In May 2014, dalbavancin was approved by the FDA for treating Gram-positive skin infections.130

Oritavancin (15, Table 3 and Fig. 2) is a synthetic analog of vancomycin derived from chloroeremomycin, and it differs by the addition of a lipophilic \( N \)-4-(4-chlorophenyl)benzyl side chain.131 The heptapeptide core shares the same structure as vancomycin, and the glycosylation is the same as that of chloroeremomycin. This structural alteration imparts improved activity against both vancomycin-susceptible \textit{Enterococcus} (VSE) and vancomycin-resistant \textit{Enterococcus} (VRE).132,133 The lipophilic side chain in oritavancin anchors the compound to the cell membrane through hydrophobic interactions and at the same time stabilizes the oritavancin dimer.133–135 Oritavancin shares a similar mechanism of action to bind the \( \alpha \)-Ala-\( \alpha \)-Ala stem termini in Gram-positive bacteria for inhibiting transglycosylation during peptidoglycan synthesis.132,136 Oritavancin is stable in vivo and is excreted as unchanged.137 Oritavancin has a very long half-life of 393 hours, which saves dosing frequency in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).138

Caspofungin, micafungin and anidulafungin (16, 17 & 18, Table 3 and Fig. 2) all belong to the cyclic hexa-lipopeptide family. They share the same cyclic peptide core structure by targeting the enzyme 1,3-\( \beta \)-glucan synthase for synthesizing glucan in the cell wall.139,140 The cyclization was formed by amidation between the sidechain of the first N-terminal residue of lysine and the C-terminus of the peptide chain.141 All three antifungal drugs have clinical efficacy against invasive candidiasis and other forms of systemic mycoses.142 Caspofungin is a semisynthetic analog of pneumocandin B0, a natural lipophilic cyclic peptide that was isolated from the fungus \textit{Glarea lozoyensis} in 1985 and approved for treating yeast and fungal infections under certain conditions in 2001.143,144 Caspofungin has a half-life of about 9 days and the majority undergoes ring-opening metabolic hydrolysis and \( N \)-acytlation.145 Only around 1.4% is excreted unchanged in urine.146 Micafungin is a semisynthetic analog of the natural cyclic hexapeptide FR901379, by enzymatic deacetylation of the N-terminal palmitoyl group and chemical reacetylation to the optimal \( N \)-acyl isoxazole analog.147 Micafungin has a poor oral bioavailability and is only intended for parenteral use with a half-life of around 15 hours.148 The majority of micafungin is metabolized by enzymatic modification of sidechains and excreted to the feces.149 Anidulafungin is also a semisynthetic echinocandin-class cyclic hexapeptide. Anidulafungin is semisynthesized from echinocandin B by diacylation to remove the linoleoyl side chain, followed by three more steps, including reacetylation with the terphenylacyl chain.150,151 Anidulafungin can inhibit invasive candidiasis \textit{via} noncompetitive inhibition of beta-(1,3)-glucan-synthase and has good clinical efficacy.152 Anidulafungin has a low oral bioavailability of 2–7% and is administered parenterally.153 The half-life of anidulafungin is 27 hours, and the majority is metabolized to a linear peptide by ring-opening hydrolysis. 10% of the administered anidulafungin remains unchanged and 30% of the radioactivity of administered anidulafungin is excreted in the feces and 1% in the urine.154

Fig. 2 The chemical structures of cyclic peptide antimicrobial agents from Table 3.
A lesson from the withdrawn cyclic peptide drug

In the past two decades, Omontys (peginesatide) was the only cyclic peptide drug withdrawn. Peginesatide contains two identical cyclic peptides of 21 amino acids attached to a 40 kDa polyethylene glycol (PEG) chain. In the bone marrow, peginesatide binds to the erythropoietin receptor (EpoR) for stimulating the production of red blood cells from erythroid progenitor cells (erythropoiesis).158,159 The FDA approved peginesatide for the treatment of anemia in adults on dialysis for chronic kidney disease in March 2012. Peginesatide was withdrawn from the US market in February 2013 due to serious Adverse Drug Reaction (sADR) of a high rate of anaphylactic reactions observed in 28 out of 20,000 patients during the first dose IV administration.157 It is unclear what causes peginesatide sADR, but it is unlikely that it has a connection with the cyclic peptide motifs itself.158

Perspectives and conclusions

Cyclic peptides have received increasing attention as a unique category of substances with many advantageous characteristics as drugs in comparison to small molecules and macromolecular antibodies. Natural peptides have been the major source of approved cyclic peptides in the last century due to the large number of cyclic peptides present in nature. The generation of specific biological functions by natural evolution also contributed to the drug development of cyclic peptides. Cyclic peptide hormones, such as oxytocin and vasopressin, are potent and selective agonizers and were used in clinics for a long time. Antagonizing cyclic peptides, such as the large number of toxins used by diverse species against competitors and prays, are widely present in nature and are a rich source for drug development.

In the past two decades, the primary trend in peptide drug discovery has been the shift of naturally isolated cyclic peptides toward cyclic peptide analogs optimized for improving potency, stability and pharmacokinetic properties. By incorporating aromatic naphthalene and tryptophan into lanreotide, its nanotubes with supramolecular packing were stabilized, which contributed to its extended half-life and ability to suppress hormone levels and activities. From a technical perspective, cyclic peptide drug development benefited from rapid lead discovery with adjustable and expandable optimization by chemical synthesis, which was the milestone in peptide drug development. The mutation of the lipophilic side chain of oritavancin prolonged its half-life and enhanced coverage against several vancomycin-resistant bacteria. Fermentation of cyclic peptides also benefited from modern molecular biology technologies, and the primary sequences of enzymes could be rapidly mutated and optimized for achieving a higher production yield. Increased expression of echinocandin B deacetylase in the production host significantly increased the transcription and bioconversion efficiency of anidulafungin. The convenience to incorporate nonnatural elements helped to improve not only the potency, but also the stability and pharmacokinet/pharmacodynamic properties. Noncanonical amino acids were introduced to improve proteomic resistance. Amino acids with hydrophobic long side chains were incorporated for extending plasma retention time and introducing extra biological activities of cyclic peptides. The population of Fmoc based solid-phase peptide synthesis technologies also greatly reduced the cost of production and promoted cyclic peptide research in individual groups.

The combination of modern recombinant technologies and peptide chemistry has solved the major problems of cyclic peptide production, mutation and optimization of the primary sequences. However, the space of optimizing natural cyclic peptides for achieving cyclic peptide drugs is limited due to the expanded desire to develop cyclic peptide ligands targeting diverse proteins. Recent development of cyclic peptide discovery was characterized by the generation of combinatorial libraries that can cover a much larger chemical space and the development of novel screening methodologies for identifying binders and inhibitors.4,159,160 Split-and-mix cyclic peptide libraries could be synthesized with millions of diversities and screened against various targets.161–167 However, the difficulties associated with sequence identification of cyclic peptides by partial Edman degradation or mass spectrometry limited the applications of one bead-one peptide library. Directed evolutions with genetically displayed cyclic peptide recombinant libraries are increasingly playing more important roles in next-generation cyclic peptide drug discovery. Display systems such as mRNA display,168–171 DNA display172 and phage display22,173,174 offer the advantages of large library diversity and rapid screening, and have resulted in the discovery of a good portion of cyclic peptides in clinic development. Compared with the typical diversity of only a few thousands for conventional natural and synthetic cyclic peptide libraries, the diversity of cyclic peptide libraries built by genetic recombinant technologies is several orders higher. The introduction of various cyclization strategies, noncanonical amino acids and even functional moieties have further increased the functionality of recombinant libraries, such as chemical stability, metabolic stability and uniform conformation. The development of selection strategies also enabled the discovery of cyclic peptides that have special properties such as cell membrane permeation ability and oral bioavailability.

A second trend in cyclic peptide drug discovery is the development of cyclic peptide conjugates to achieve a selective delivery of different effector molecules to target tissue. Besides the drug itself, which induces the desired biological functions, and the linker, which controls drug release, cyclic peptides have been investigated intensively to facilitate sufficient target selectivity for engineering cyclic peptide drug conjugates (PDCs). Cyclic peptides, possessing the characteristics of both antibodies and small molecules, have the capacity to penetrate tissue freely and deeply, and selectively and effectively interact with receptors that are specific for certain cell types. Furthermore, PDCs are more advanced for low immunogenicity, large-scale synthesis using solid-phase synthesis, low production
cost, and relatively good pharmacokinetics. When conjugated with chemotherapeutic or cytotoxic agents, PDCs have effects on tumor growth inhibition and elimination. Cyclic peptides are also conjugated with positron-emitting radioisotopes and gamma-emitting radioisotopes for developing positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging agents.

In the coming decades, the position of cyclic peptides in the pharmaceutical industry is expected to outperform small molecules and antibodies in certain applications due to their structural complexity, large surface binding area and relatively small size. Orally available cell penetrating peptides will be one of the most important focuses of cyclic peptide studies, and the reduced production cost of cyclic peptides will contribute to the growth of cyclic peptide development.

Conflicts of interest
There are no conflicts to declare.

Acknowledgements
This work was supported by Shanghai Pujiang Program, Science and Technology Commission of Shanghai Municipality (#20P1415900 to S. C.).

References

33 Approval Date(s) and History, Letters, Labels, Reviews for ISTODAX. Available from: https://www.accessdata.fda.gov/scripts/cder/def/index.cfm?event=overview.process&ApplNo=022393.
34 Approval Date(s) and History, Letters, Labels, Reviews for LUPKYNIS. Available from: https://www.accessdata.fda.gov/scripts/cder/def/index.cfm?event=overview.process&ApplNo=213716.
44 Drug Approval Package for lupkinsy. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000TOC.cfm.
58 Approval Date(s) and History, Letters, Labels, Reviews for PRIALT. Available from: https://www.accessdata.fda.gov/scripts/cder/def/index.cfm?event=overview.process&ApplNo=021060.


149 J. Houst, J. Spizek and V. Havlicek, Antifungal Drugs, Metabolites, 2020, 10, 3.


